Table 2.
Differences between cancer and benign patient’s urine protein expression in ELISA study of transurethral resection of bladder tumor patients
| Benign | Cancer | p-value | |
|---|---|---|---|
| No. of participants | 25 | 95 | |
| Raw data | |||
| A2M | 76,897.4 (4,579.0 to 35,307.0) | 159,609.5 (1,429.5 to 224,686.5) | 0.045 |
| CFL1 | 16,766.87 (2,242.5 to 14,108.0) | 33,026.01 (3,692.0 to 65,795.5) | 0.017 |
| APOA1 | 6,779,594.0 (175,659.0 to 1,158,217.0) | 19,927,277.3 (703,284.5 to 18,851,324.0) | 0.061 |
| ITIH2 | 8.07 (3.42 to 3.68) | 7.29 (0.33 to 3.45) | 0.875 |
| AFM | 12,894.0 (716.0 to 13,301.0) | 48,942.7 (1,997.5 to 46,017.0) | 0.002 |
| FGB | 256,907.1 (6,421.0 to 160,181.0) | 673,964.6 (26,786.75 to 731,388.5) | 0.039 |
| CDC5L | 2.45 (1.98 to 2.74) | 2.85 (2.08 to 3.45) | 0.034 |
| CD5L | 272.0 (88.70 to 189.72) | 508.5 (130.90 to 511.93) | 0.038 |
| After logarithmic transformation | |||
| ln_ITIH2 | 1.28 (1.22 to 1.30) | 0.11 (−1.11 to 1.24) | < 0.001 |
| ln_AFM | 7.85 (6.57 to 9.50) | 9.26 (7.60 to 10.74) | 0.003 |
| ln_CD5L | 5.06 (4.49 to 5.25) | 5.57 (4.87 to 6.24) | 0.023 |
| ln_APOA1 | 13.22 (12.08 to 13.96) | 15.05 (13.46 to 16.75) | 0.001 |
| ln_FGB | 10.64 (8.77 to 10.20) | 11.6 (10.20 to 13.49) | 0.049 |
A2M, alpha-2 macroglobulin; AFM, afamin; APOA1, apolipoprotein A-I; CD5L, CD5 antigen-like protein; CDC5L, cell division cycle 5-like protein; CFL1, cofilin-1; ELISA, enzyme-linked immunosorbentassay; FGB, fibrinogenbeta chain; ITIH2, inter-alpha-trypsin inhibitor heavy chain H2.